PT-141 10 mg

PT-141 10 mg contains bremelanotide, a melanocortin receptor agonist. The FDA-approved product (Vyleesi) is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). In non-medical bodybuilding contexts, it is sometimes referenced for libido support during anabolic steroid cycles, though such use falls outside approved indications.

The FDA-approved dosing is 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, with no more than one dose within 24 hours and no more than 8 doses per month. Community protocols often reference starting at lower doses (0.5–1 mg) to establish tolerance, and spacing doses at least 48–72 hours apart to preserve responsiveness.

No. PT-141 acts on melanocortin receptors in the central nervous system rather than the hypothalamic-pituitary-gonadal axis. It does not suppress endogenous testosterone production and does not require post-cycle therapy.

Bremelanotide is a melanocortin receptor agonist that binds MC3R and MC4R in the central nervous system, generating sexual desire and arousal through central mechanisms. Unlike PDE5 inhibitors which act on the vascular system, it works in the brain to influence sexual motivation.

The FDA label states administration at least 45 minutes before anticipated sexual activity. The plasma half-life is approximately 2.7 hours, but subjective effects commonly last 6–24 hours or longer, with some users reporting residual effects for up to 48 hours.

There is no single “best” compound for libido. PT-141 addresses central desire mechanisms, while PDE5 inhibitors such as Cialis and Viagra address peripheral blood flow. The two mechanisms are complementary and are sometimes combined. The appropriate choice depends on individual circumstances.

Viagra (sildenafil) is a PDE5 inhibitor that acts on the vascular system to improve penile blood flow. PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on the central nervous system to generate desire and arousal. A 2005 study found that combining bremelanotide with sildenafil produced a greater erectile response than either alone.

Melanotan 2 is a non-selective melanocortin agonist that binds MC1R through MC5R, producing tanning effects alongside sexual arousal. PT-141 was derived from melanotan II research but has a modified structure that alters receptor selectivity, with effects more focused on sexual desire. Stacking the two at full doses is generally advised against due to overlapping melanocortin receptor activation.

1.75 mg is the FDA-approved dose for Vyleesi, administered subcutaneously. In community contexts, some users start at lower doses (0.5–1 mg) to assess tolerance before moving to the full dose. The 10 mg vial contains multiple doses at these levels.

PT-141 10 mg is labeled at 10 mg of Bremelanotide (PT-141) per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.

No published laboratory report is currently available for this specific product. Product potency and purity verification would apply to tested samples only and should not be interpreted as a measurement of every vial or production batch.

Lyophilized PT-141 is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution.